HALIFAX, March 5 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF) a global market leader in premium rapid diagnostic solutions,
announced today that it will host a conference call with analysts to discuss
the company's second quarter financial results and provide a corporate update
beginning at 9:00 am EST (10:00 am AST) on Wednesday, March 7, 2007. MedMira's
second quarter financial results were released on March 1, 2007 and are
available on the MedMira website at www.medmira.com.
In order to listen to the conference call, please dial 1-800-589-8577
toll-free anywhere in Canada or the USA, or 1-416-644-3425 in the Toronto
A replay of the call will be available until 23:59 pm EST, Wednesday,
March 14, 2007 and may be accessed by dialing 1-877-289-8525 toll-free
anywhere in Canada or the USA, or 1-416-640-1917 in the Toronto area, and
entering the pass code 21222235# anytime after the call has ended.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
The company's corporate offices and manufacturing facilities are located
in Halifax, Nova Scotia, Canada with a representative office in China. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations, (902)
450-1588, firstname.lastname@example.org; Andrea Young, Corporate Communications, (902)